Fiscal Year 2023 Financial Guidance
Surmodics now expects fiscal year 2023 total revenue to range from $103 million to $106 million vs. $104.35M consensus, representing an increase of 3% to 6% compared to the prior year. The company’s prior guidance called for fiscal year 2023 total revenue to range from $102 million to $106 million, representing an increase of 2% to 6% compared to the prior year.
The company now expects fiscal 2023 GAAP diluted loss per share to range from $(2.30) to $(2.00). The company’s prior guidance called for fiscal 2023 GAAP diluted loss per share to range from $(2.40) to $(2.00).
Non-GAAP diluted loss per share in fiscal 2023 is expected to range from $(1.98) to $(1.68) vs. -$1.93 consensus. The company’s prior guidance called for fiscal 2023 Non-GAAP diluted loss per share in fiscal 2023 to range from $(2.09) to $(1.69).
